Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

Donanemab is a targeted antibody drug which slows the early stages of Alzheimer’s. Alzheimer’s Research UK said Nice's announcement “risks signalling that the UK is no longer a good place to launch ...

The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare ...

Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...